Theravance Biopharma (TBPH) Stock Price, News & Analysis

Company Overview

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S. Food and Drug Administration for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

In addition to its marketed respiratory franchise, Theravance Biopharma maintains a diversified pipeline with clinical-stage programs in immunology and rare disease. Its immunology efforts include a gut-selective pan-JAK inhibitor being evaluated for inflammatory bowel diseases, while its rare disease portfolio features a norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension. The company leverages internal research capabilities alongside collaborations and partnerships to advance its small-molecule candidates through clinical and regulatory milestones.

Founded in 1998 as part of a respiratory research group of GlaxoSmithKline and later spun out as an independent entity in 2014, Theravance Biopharma is headquartered in South San Francisco, California. It operates research facilities in the Bay Area and maintains corporate offices in Dublin, Ireland, supporting its global clinical programs. The company’s leadership team, under President and Chief Executive Officer Rick E. Winningham, brings deep expertise in pharmaceutical R&D, regulatory affairs and commercial strategy aimed at delivering new therapeutic options to patients worldwide.

Key Stats

• Today's Range: $13.65 to $14.25
• 50-Day Range: $10.90 to $14.47
• 52-Week Range: $7.88 to $14.55
• Volume: 377,753 shs
• Average Volume: 489,611 shs
• Market Capitalization: $708.57 million
• P/E Ratio: 58.63
• Dividend Yield: N/A
• Price Target: $23.00
• Consensus Rating: Buy

Theravance Biopharma Stock Analysis - MarketRank™

Theravance Biopharma scored higher than 66% of companies evaluated by MarketBeat, and ranked 327th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Buy

Consensus Rating

Theravance Biopharma has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Theravance Biopharma has a consensus price target of $23.00, representing about 63.5% upside from its current price of $14.07.

Amount of Analyst Coverage

Theravance Biopharma has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Theravance Biopharma are expected to grow in the coming year, from ($1.09) to $0.35 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Theravance Biopharma is 58.63, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 298.08.

Price to Earnings Ratio vs. Sector

The P/E ratio of Theravance Biopharma is 58.63, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 348.68.

Price to Book Value per Share Ratio

Theravance Biopharma has a P/B Ratio of 3.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.63% of the float of Theravance Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Theravance Biopharma has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Theravance Biopharma has recently increased by 25.28%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Theravance Biopharma does not currently pay a dividend.

Dividend Growth

Theravance Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.63% of the float of Theravance Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Theravance Biopharma has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Theravance Biopharma has recently increased by 25.28%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.34

News Sentiment

Theravance Biopharma has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Theravance Biopharma this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for TBPH on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Theravance Biopharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Theravance Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $227,800.00 in company stock.

Percentage Held by Insiders

Only 6.90% of the stock of Theravance Biopharma is held by insiders.

Percentage Held by Institutions

99.10% of the stock of Theravance Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TBPH Stock Analysis - Frequently Asked Questions

How have TBPH shares performed this year?

Theravance Biopharma's stock was trading at $9.41 at the beginning of the year. Since then, TBPH stock has increased by 49.5% and is now trading at $14.07.

How were Theravance Biopharma's earnings last quarter?

Theravance Biopharma, Inc. (NASDAQ:TBPH) posted its earnings results on Thursday, May, 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.16. The biopharmaceutical company had revenue of $15.39 million for the quarter, compared to analyst estimates of $28.08 million. Theravance Biopharma had a trailing twelve-month return on equity of 6.93% and a net margin of 16.88%.
Read the conference call transcript.

Who are Theravance Biopharma's major shareholders?

Top institutional shareholders of Theravance Biopharma include Geode Capital Management LLC (1.79%), Bank of America Corp DE (1.08%), Camber Capital Management LP (0.90%) and BNP Paribas Financial Markets (0.77%). Insiders that own company stock include Richard A Graham and Rhonda Farnum.
View institutional ownership trends.

How do I buy shares of Theravance Biopharma?

Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Theravance Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Theravance Biopharma investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 9/22/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TBPH
• Previous Symbol: NASDAQ:TBPHV
• CIK: 1583107
• Web: www.theravance.com
• Phone: (650) 808-6000
• Fax: N/A
• Employees: 110
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Theravance Biopharma: $23.00
• High Price Target: $28.00
• Low Price Target: $15.00
• Potential Upside/Downside: +63.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.24
• Trailing P/E Ratio: 58.63
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$56.42 million
• Net Margins: 16.88%
• Pretax Margin: 51.91%
• Return on Equity: 6.93%
• Return on Assets: 3.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.70
• Quick Ratio: 6.70

Sales & Book Value

• Annual Sales: $64.38 million
• Price / Sales: 11.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.57 per share
• Price / Book: 3.94

Miscellaneous

• Outstanding Shares: 50,360,000
• Free Float: 46,886,000
• Market Cap: $708.57 million
• Optionable: Optionable
• Beta: 0.04